TOP HEADLINES

Featured Story

UPDATED: Janssen recalls 13,500 bottles of Xarelto because of contamination

Johnson & Johnson's Janssen unit is recalling 13,500 bottles of its top-selling anticoagulant Xarelto because of microbial contamination.

BARDA calls on Novartis, GSK, Emergent to pitch in with Ebola drug

The U.S. government invested $440 million in three vaccine plants in the U.S. in 2012 with the proviso that if something like a pandemic occurred, it could call on them to produce drugs that it required. With Ebola spreading, those calls have now been made.

Mylan recalls blood pressure med, following recalls of generic by two other drugmakers

Another drugmaker is having to recall metoprolol succinate extended release tablets, a generic for AstraZeneca hypertension drug Toprol XL. This time it is Mylan and the recall is for nearly 16,000 bottles of the beta blocker.

FDA will start the new year with its Office of Quality in place

The Office of Pharmaceutical Quality will finally open Jan. 1, and the FDA's Janet Woodcock will serve as its first acting director.

FDA bans maker of suspect Chinese heparin

The FDA has taken steps against a Chinese heparin maker it says is using potentially tainted raw supplies and which refused to let inspectors get a good look at its plants or records so that it could find out for sure.

MORE NEWS

From Our Sister Sites

FiercePharma

A few potential deals have already caved under the weight of new U.S. tax rules that discourage inversion deals. Not Mylan's. The Pittsburgh-based company is pushing ahead with a $5.3 billion plan to buy a piece of Abbott Laboratories' overseas generics business--with a few edits, of course.

FierceMedicalDevices

Med merger mania is leaving no stone unturned, even sterilization services. On the heels of Steris's bid for Britain's Synergy Health in another inversion deal, private equity firm GTCR is looking to unload SterigenicsĀ International, another sterilization company, for $1.5 billion, including debt.